牛牛AI助理已提取核心訊息
On March 4, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer (CFO). Dr. Plunkett is recognized for his extensive experience in the biopharmaceutical sector, including his recent role as CFO at Aeovian Pharmaceuticals and his leadership in the Nasdaq IPOs of Imago Biosciences and Nkarta Therapeutics. His appointment is seen as a strategic move for Apollomics as the company progresses with its clinical, regulatory, and commercialization plans, particularly for its lead drug candidates vebreltinib and uproleselan. The company, which focuses on developing oncology therapies, has a pipeline of nine drug candidates, with six in clinical development. The announcement was made via a press release, which is furnished with the SEC but not deemed 'filed' for legal purposes.
On March 4, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer (CFO). Dr. Plunkett is recognized for his extensive experience in the biopharmaceutical sector, including his recent role as CFO at Aeovian Pharmaceuticals and his leadership in the Nasdaq IPOs of Imago Biosciences and Nkarta Therapeutics. His appointment is seen as a strategic move for Apollomics as the company progresses with its clinical, regulatory, and commercialization plans, particularly for its lead drug candidates vebreltinib and uproleselan. The company, which focuses on developing oncology therapies, has a pipeline of nine drug candidates, with six in clinical development. The announcement was made via a press release, which is furnished with the SEC but not deemed 'filed' for legal purposes.
2024年3月4日，處於臨床階段的生物製藥公司Apollomics Inc. 宣佈任命馬修·普倫基特博士爲其新任首席財務官（CFO）。普倫基特博士因其在生物製藥領域的豐富經驗而獲得認可，包括他最近在Aeovian Pharmicals擔任首席財務官以及他在Imago Biosciences和Nkarta Therapeutics的納斯達克首次公開募股中的領導地位。他的任命被視爲Apollomics的一項戰略舉措，因爲該公司正在推進其臨床、監管和商業化計劃，特別是其主要候選藥物vebreltinib和uproleselan。該公司專注於開發腫瘤療法，目前有九種候選藥物，其中六種正在臨床開發中。該公告是通過新聞稿發佈的，該新聞稿由美國證券交易委員會提供，但出於法律目的未被視爲 “已提交”。
2024年3月4日，處於臨床階段的生物製藥公司Apollomics Inc. 宣佈任命馬修·普倫基特博士爲其新任首席財務官（CFO）。普倫基特博士因其在生物製藥領域的豐富經驗而獲得認可，包括他最近在Aeovian Pharmicals擔任首席財務官以及他在Imago Biosciences和Nkarta Therapeutics的納斯達克首次公開募股中的領導地位。他的任命被視爲Apollomics的一項戰略舉措，因爲該公司正在推進其臨床、監管和商業化計劃，特別是其主要候選藥物vebreltinib和uproleselan。該公司專注於開發腫瘤療法，目前有九種候選藥物，其中六種正在臨床開發中。該公告是通過新聞稿發佈的，該新聞稿由美國證券交易委員會提供，但出於法律目的未被視爲 “已提交”。
有用
沒用